Rückruf von Libtayo (Cemiplimab) 350 mg Konzentrat zur Herstellung einer Infusionslösung (EU/1/19/1376/001, Charge 8494100007) aufgrund eines Qualitätsmangels: Verbördelungsfehler
Paul-Ehrlich-Institut · July 29, 2026
Recall: Libtayo (Cemiplimab) 350 mg concentrate for infusion solution, batch 8494100007, quality defect
Original title: Informationsschreiben von Regeneron GmbH: Libtayo (Cemiplimab)
Regeneron recalls one batch of Libtayo (Cemiplimab) 350 mg due to a sealing defect in the vial.
Published by Paul-Ehrlich-Institut. HealthSignal links to the original document; the summary above is extracted from the source text.